Built For Patients
Guided By Biology.
Jabez is a lean, drug development biotech company, purpose-built to translate academic discoveries into impactful cancer therapies.
Watch our short animated explainer video to understand our technology, below.
OUR PHILOSOPHY
At Jabez, we are developing a smarter model for cancer therapy.
At the core of Jabez’s strategy is a therapeutic framework we call 3-S Therapeutics – cancer treatments that are:
Seamless – Easy-to-take
Orally available, low-toxicity, outpatient-compatible to maximize compliance.
Scalable – Easy-to-make
Scalable synthesis, efficient manufacturing, global potential
Synergistic – Built to Integrate
Rationally synergistic with standard-of-care treatments
We are experts in...
Drug Development
Our leadership team brings deep expertise in identifying promising assets, advancing them through the clinic, and navigating regulatory pathways. With this focus, we’re uniquely positioned to translate academic discoveries into real-world therapeutic impact – something that is desperately needed in the oncology industry.
Tamara Jovonovich, PhD
CEO & Co-Founder
Tamara is a highly experienced biotech operator with over 20 years in pharmaceutical development and 15 FDA drug approvals
Robert Lewis
COO & Co-Founder
Rob Lewis has over 30 years in pharmaceutical development and has overseen 30 FDA drug approvals.
Our clinical partners:
INVEST IN JABEZ
We’re raising investment to reach key clinical and commercial milestones.
We are now offering a pre-IPO investment opportunity, open to both accredited and non-accredited investors under a Regulation A+ offering.
Advance Our Lead Program
Establish safety, expand to synergistic indications (e.g., AML, MM), and demonstrate proof-of-concept for the Jabez model.
Demonstrate 3-S Clinical Impact
We aim to show that 3-S therapeutics can drive real-world outcomes – improving efficacy without added toxicity or logistical burden.
Expand Our Portfolio
We will identify and license additional assets that fit our 3-S filter to build a pipeline of smart, synergistic therapeutics.
Scale the Jabez Model
With each successful program, we expand our ability to systematically evaluate, acquire, and deploy high-impact therapies.
Featured Video
Jabez Biosciences: A Smarter Model for Cancer Therapy
- Video Overview
The biotech industry is pouring billions into AI platforms and supercomputers to reinvent drug discovery from scratch. But when it comes to cancer, there’s a faster, more cost-effective way: tap into the massive reservoir of high-quality, target-validated research already emerging from academia.
CLINICAL DEVELOPMENT
Our Clinical Trials
Jabez Biosciences is proud to be a clinical-stage biotechnology company. We are currently enrolling patients in a Phase 1 clinical trial evaluating our lead candidate in advanced solid tumors and non-Hodgkin lymphoma.
Latest
News & Events
- 06.23.25
- News
Multi-institutional team awarded NCI grant to open novel AML trial
- 05.09.25
- News
Jabez Biosciences, Inc. Announced Phase 1 Clinical Trial of JBZ-001 at AACR 2025
- 04.03.25
- News
